Home » Pipeline
Pipeline
April 9, 2018
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| Wize Pharma, Inc. | LO2A | moderate to severe Conjunctivochalasis (CCH) | Phase II trials initiated enrolling 62 subjects |
| Synlogic | SYNB1020 | hyperammonemia in patients with cirrhosis | Phase Ib/IIa trials initiated |
| Amylyx Pharmaceuticals, Inc. | AMX0035 | Amyotrophic lateral sclerosis (ALS) | Phase II open-label extension initiated enrolling 132 patients in the U.S. |
| Rigel Pharmaceuticals | fostamatinib | IgA nephropathy (IgAN) | Phase II topline results announced evaluating subjects in the U.S., Asia and Europe |
| Kazia Therapeutics Limited | GDC-0084 | glioblastoma multiforme (GBM) | Phase II trials initiated |
| Eli Lilly and Company | Cyramza (ramucirumab) | hepatocellular carcinoma (HCC) | Phase III positive topline results announced evaluating 292 patients across 20 countries in North America, Asia, Europe and Latin America |
| Allergan, Inc. and Gedeon Richter Ltd. | cariprazine | bipolar I depression | Phase III positive topline results announced evaluating 493 subjects |
| GenSight Biologics | GS010 (rAAV2/2-ND4) | Leber Hereditary Optic Neuropathy (LHON) | Phase III topline results announced evaluating 37 subjects |
| Wize Pharma, Inc. | LO2A | dry-eye syndrome (DES) in patients with Sjögren's syndrome | Phase IV trials initiated enrolling 60 subjects |
| TARIS Biomedical | TAR-200 (GemRIS) | organ-confined or locally-advanced Muscle Invasive Bladder Cancer | Fast Track Designation granted |
| Tetra Discovery Partners | BPN14770 | Fragile X Syndrome | Orphan Drug Designation granted |
| PharmAbcine Inc. | TTAC-0001 | Glioblastoma Multiforme (GBM) | Orphan Drug Designation granted |
| Scholar Rock | SRK-015 | spinal muscular atrophy (SMA) | Orphan Drug Designation granted |
| AstraZeneca | moxetumomab pasudotox | hairy cell leukemia (HCL) | Priority Review granted |
| Dr. Reddy’s Laboratories Ltd. | DFN-02 | migraine | NDA filed with the FDA |
| AstraZeneca Pharmaceuticals LP | BYDUREON | type 2 diabetes with inadequate glycemic control | FDA approval granted |
| Amgen | Blincyto (blinatumomab) | B-cell precursor acute lymphoblastic leukemia (ALL) | FDA approval granted |
